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Background/Aims: Enhanced replication of hepatitis C virus (HCV) is well described in the setting of moderate to severe 
immunosuppression. The aims of this retrospective study were to determine the incidence of enhanced HCV replication in 
hepatocellular carcinoma (HCC) patients undergoing transarterial chemolipiodolization (TACL) and to identify the factors 
associated with enhanced replication of HCV. The clinical pattern of enhanced HCV replication was compared with 
hepatitis B virus (HBV) reactivation during TACL. Methods: This study enrolled 49 anti-HCV-seropositive patients who 
were diagnosed with HCC between January 2005 and December 2010 and who underwent TACL using epirubicin and/or 
cisplatin with consecutive HCV RNA copies checked. For comparison, 46 hepatitis B surface antigen
1-positive patients 
with HCC who were treated with TACL were also enrolled. The frequency, associated factors, and clinical outcomes of 
enhanced HCV replication were analyzed and compared with those of HBV reactivation during TACL. Results: Enhanced 
replication of HCV occurred in 13 (26.5%) of the 49 anti-HCV-seropositive patients during TACL. Of these 13 patients, 4 
developed hepatitis, but none of the subjects developed decompensation due to the hepatitis. No significant clinical 
factors for enhanced HCV replication during TACL were found. Compared with HBV reactivation, the frequency of 
hepatitis attributed to enhanced HCV replication was significantly lower than that for HBV reactivation (8.2% vs. 23.9%, 
P=0.036). Conclusions: TACL can enhance HCV replication; however, the likelihood of hepatitis and decompensation 
stemming from enhanced HCV replication was lower than that for HBV reactivation in patients undergoing TACL. (Korean 
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INTRODUCTION
Hepatitis C virus (HCV) is a major public health problem, 
with approximately 170 million people infected, corresponding 
to about 3% of the population worldwide. HCV causes a 
high rate of chronic infection, resulting in severe complications 
of chronic liver disease such as liver cirrhosis (LC) and 
hepatocellular carcinoma (HCC).
1 Regarding disease progression, 
the host immune response has a unique role in HCV 
infection because it contributes not only to viral control and 
clinical recovery but also to chronic hepatitis and liver 
cirrhosis. The coordinated activities of cellular immune 
responses are initiated on antigen-presenting cells and play 
critical roles in the control of HCV replication. However, 
mutations in viral epitopes targeted by cytotoxic CD8+ T 
cells can allow the virus to escape immune-mediated 300  The Korean Journal of Hepatology Vol. 17. No. 4, December 2011
clearance, leading to chronic hepatitis and liver cirrhosis.
2
An immune-compromised status, such as after liver 
transplantation, can enhance HCV viral replication, and it is 
probably secondary to impairment of cellular immunity. 
Likewise, data from patients infected with HCV receiving 
cytotoxic chemotherapy for hematological malignancies 
show that liver dysfunction by enhanced replication of HCV 
may be a possible complication, whereas it is less common 
and less severe than that due to hepatitis B virus (HBV) 
reactivation.
3-5 However, cases of severe hepatitis with 
hepatic decompensation from enhanced HCV replication 
have been reported.
5
Transarterial chemo-embolization (TACE) has become 
the most common non-surgical management for unresectable 
HCC. Because TACE increases the survival rates in patients 
with unresectable HCC, it is currently considered the primary 
therapy.
6-8 However, TACE is not indicated for those with 
poor hepatic reserve, as it is related to more complications 
and worse prognoses in those cases. Yoshikawa et al
9 
indicated that transarterial chemo-lipiodolization (TACL) 
may be a successful alternative for the palliative treatment of 
high-risk HCC patients with poor hepatic reserve. Using an 
infusion of a lipiodol emulsion mixed with anticancer drugs 
via the hepatic artery, micro-embolization of tumor vessels 
and slow release of anticancer drugs from the lipiodol were 
achieved. However, this procedure can also lead to worsening 
of liver function, although the frequency was relatively low.
9
TACL was reported to possibly reactivate HBV replication 
in HBsAg-positive HCC patients irrespective of baseline 
viral status.
10 According to that study, performed at our 
institution, HBV reactivation during TACL resulted in 
hepatitis, hepatic decompensation, and even death.
10 However, 
no detailed study has examined enhanced HCV replication 
in HCC patients during TACL. In this retrospective study, 
the frequency, associated factors, and clinical outcomes of 
enhanced HCV replication were analyzed and compared 
with those of HBV reactivation during TACL.
PATIENTS AND METHODS
Patients
From January 2005 to December 2010, 71 patients who 
were diagnosed with unresectable HCC at Liver Clinics of 
Seoul St. Mary’s Hospital and Incheon St. Mary’s Hospital, 
were positive for anti-HCV antibody, and who had both 
basal and follow-up HCV RNA titers checked were included 
in the study. The exclusion criteria for these patients were as 
follows: extrahepatic metastasis, main portal vein thrombosis, 
and positive results for HBs Ag or human immunodeficiency 
virus (HIV). As a result, 13 patients were excluded from the 
analysis. Primary treatments for the remaining 58 patients 
were TACL (n=49), external radiation (including cyberknife 
therapy) (n=3), and conservative management (n=6). The 
diagnosis of HCC was based on histologic evidence or 
elevated serum α-fetoprotein (AFP) levels (>400 ng/mL) 
with typical radiologic findings.
For the comparisons, 116 consecutive patients with positive 
HBsAg newly diagnosed with unresectable HCC were 
included. Patients were excluded from the study if they 
fulfilled any of the following criteria: a previous history of 
antiviral therapy for HBV, extrahepatic metastasis, a serum 
HBV DNA level greater than 10
7 copies/mL, main portal 
vein thrombosis, or positive tests for antibody to hepatitis C 
virus or human immunodeficiency virus. Finally, 46 patients 
were eligible for analysis. There was a discrepancy in the 
year of enrollment between HCV and HBV seropositive 
groups because preemptive lamivudine treatment during 
TACL has been used after February 2005.
Laboratory tests
Seropositivity for anti-HCV antibody was determined 
using third-generation enzyme immunoassays (Abbott Labo-
ratories, North Chicago, IL, USA). Baseline HCV RNA 
titers were checked before commencement of treatment, and 
follow-up titers were checked before each course of treatment 
using real-time polymerase chain reaction (Biosewoom, Inc. 
Seoul, Korea). All patients were followed up at intervals of 
less than 2 months. At baseline, HCV genotype was determined 
by the VERSANT HCV genotype assay (LiPA 2.9, Belgium). 
All patients were tested for HBsAg, antibodies to HBsAg 
(anti-HBs) (Abbott Laboratories, IL, USA), and HIV at the 
time of enrollment. Serum aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), albumin, bilirubin, 
alkaline phosphatase, gamma glutamyl transpeptidase, 
prothrombin time, and AFP were checked before each course 
of treatment and again when necessary. 
HBV DNA test (VERSANT 3.0, branched DNA assay, 
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range: 2×10
3 to 1×10
8 copies/mL) was performed before 
each course of treatment and again when necessary. Geno-
typing of HBV was performed via ELISA (Institute of 
Immunology, Tokyo, Japan) using monoclonal antibodies to 
the preS2 region, as previously described.
11 All patients 
were followed up at intervals of less than 2 months in a 
similar manner to those with positive anti-HCV antibodies.
TACL-related ischemic injury of the liver can also elevate 
liver enzymes, but it did not seem to last more than two 
weeks.
10 We checked the liver enzymes at least 1 month after 
prior TACL to discern hepatitis due to enhanced viral 
replication from ischemic injury.
Definitions
Enhanced replication of HCV was defined as the 
reappearance of HCV RNA for spontaneously resolved or 
treated patients or an increase of over 10 fold in serum HCV 
RNA compared with the baseline level. Hepatitis attributed 
to enhanced HCV replication was defined with a three-fold 
or greater increase in serum ALT level that exceeded 100 
IU/L (reference range, <36 IU/L) in patients with HCV 
reactivation in the absence of clinical features of tumor 
progression, hepatotoxic drugs, treatment-related hepatic 
damage, or other systemic infections. Hepatic decompensation 
during TACL was defined by the occurrence of any one of 
the following: newly developed encephalopathy or ascites, 
increase in the prothrombin time by >3 second greater than 
the level before TACL, and increase in the bilirubin level to 
twice the upper limit of normal (ULN) (reference range: 
<1.2 mg/dL) if initially normal or an increase to twice the 
baseline level if initially abnormal.
We defined HBV reactivation as reappearance or an 
increase of over 10 fold in serum HBV DNA compared with 
the baseline level, as mentioned in previous reports.
12,13 
Hepatitis attributed to HBV reactivation and hepatic decom-
pensation during TACL were defined in the same manner as 
enhanced HCV replication.
Treatment methods
The assignment of treatment options for unresectable HCC 
is done according to a standard protocol developed by the 
Barcelona Clinic Liver Cancer Group.
14 Specifically, patients 
with a single nodule less than 5 cm in diameter or up to three 
nodules less than 3 cm in diameter were considered candidates 
for radiofrequency ablation, percutaneous ethanol injection 
therapy, or liver transplantation as available. For patients 
with HCC beyond this tumor extent, transarterial chemotherapy 
was performed for Child-Pugh classification A, whereas 
suboptimal or conservative management was given for 
Child-Pugh classification B or C. TACL was usually performed 
at 1- to 2-month intervals. The chemotherapeutic regimens 
used for TACL included epirubicin (50 mg/m
2) or doxorubicin 
(25-70 mg) monotherapy, cisplatin monotherapy (60 mg/m
2), 
and epirubicin and cisplatin combination therapy. Lipiodol 
(5-10 mL) was given with each regimen during the procedure, 
but Gelfoam
® was not used. No patients were given 
glucocorticoid therapy. 
Statistical analyses
Analyses were conducted using the independent-sample 
t-test, Mann-Whitney U-test, chi-square test, or Fisher’s exact 
test, as appropriate. Two-tailed P-values <0.05 were considered 
significant. Significant variables from the univariate analysis 
were then included in a multivariate analysis using a logistic 
regression model to identify the independent predictors of 
each phenomenon. Data were analyzed using SPSS software 
(SPSS 15.0; SPSS, Inc., Chicago, IL, USA).
Ethics statement
The study was approved by the Ethics Committee of the 
Catholic University of Korea (KC11RISI0508). All subjects 
provided signed informed consent to participate in this 
research study.
RESULTS
Study population
Table 1 shows the baseline characteristics of all 95 patients 
newly diagnosed with HCC and either HCV or HBV 
seropositivity who underwent TACL as their initial modality 
of treatment. Among 49 patients positive for HCV, detectable 
HCV RNA was observed in 41 patients, and HCV RNA was 
below 50 copies/mL for eight patients. It is impossible to test 
HCV genotype in patients with HCV RNA titers below 
10,000 copies/mL, and 36 patients had HCV genotype tested. 
Among them, 19 (52.8%) patients were genotype Ib, and 17 
(47.2%) patients were other types. 
In the HBV seropositive group, eight (17.4%) patients 302  The Korean Journal of Hepatology Vol. 17. No. 4, December 2011
Table 1. Baseline characteristics of the entolled patients
HCV seropositive group (n=49) HBV seropositive group (n=46) P-value
Age (years)  66.2±9.7 54.3±9.1 < 0.001
*
Sex (M:F)  34:15  37:9  0.220
†
ALT (IU/L)  52.1±32.1 52.1±33.9  0.495
*
Total bilirubin (mg/dL, range)  1.00 (0.1-3.0)  0.87 (0.3-3.8)  0.714
*
HCV RNA (copies/mL), median (range)  656,505 (<50-52,700,000) 
HCV genotype 
Ib 19/36 (52.8%)  -  -
Other types  17/36 (47.2%)  -  -
HBV DNA (10
3 copies/mL), median (range) 37.61 (<2.0-48,756.0) 
HBeAg seropositivity  8 
AFP (ng/mL)  358.11 (3.0-2170.0) 266.71 (2.0-1201.0) 0.512
*
Tumor size (cm)  3.8±3.1 6.5±3.7 < 0.001
*
Tumor morphology  0.072
†
Uninodular 27  22 
Multinodular or diffuse  22  24 
Portal vein thrombosis  0.105
†
Present   8  14 
Absent 41  32 
Child-Pugh classification (A/B/C)  44/5/0  40/5/1  0.506
†
Type of chemotherapy  0.056
†
Epi/Doxo+Cis 32  38 
Epi/Doxo or Cis alone  17   8 
Total number of cycles  3.7±2.0 4.3±2.4 0.179
*
Values are expressed as mean±SD for continuous variables except AFP [median (range)].
*P-value by Student-t test, 
†P-value by Chi-square test.
HCV, hepatitis C virus; HBV, hepatitis B virus; ALT, alanine aminotransferase; AFP, α-fetoprotein; Epi, epirubicin; Cis, cisplatin; 
Doxo, doxorubicin.
were HBeAg-positive. For 13 patients, HBV DNA was below 
2000 copies/mL, and they were all HBeAg negative. HBV 
genotyping performed in 46 patients showed that all were 
genotype C (100%). 
The age of diagnosis and tumor size was significantly 
different between these two groups. The patients in the HBV 
seropositive group were younger, and their tumor size was 
larger. 
Enhancement of HCV replication and occurrence 
of hepatitis compared with HBV reactivation
Table 2 summarizes the frequency of enhanced viral 
replication, hepatitis attributed to enhanced viral replication 
or other causes, and hepatic decompensation. 
Among 49 HCV seropositive patients who underwent 
TACL, 26.5% (13/49) developed increased HCV replication 
during the follow-up period. Hepatitis attributed to enhanced 
HCV replication was observed in 8.2% (4/49) of patients, 
and there was no case of hepatic decompensation. Two 
patients initially had undetectable HCV RNA titers but later 
developed enhanced viral replication. One patient had no 
history of treatment, and the other had received interferon 
therapy 10 years before diagnosis of HCC. Both of these 
patients developed hepatitis attributed to enhanced viral 
replication.
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Table 2. Comparison of enhanced viral replication, hepatitis, and hepatic decompensation in the HCV- and HBV-seropositive groups 
during transarterial chemolipiodolization (TACL)
HCV seropositive
group (n=49) 
HBV seropositive
group (n=46) 
P-value
*
Enhanced replication, n (%)  13 (26.5%)  15 (32.6%)  0.521 
Baseline HCV RNA (copies/ml) (<50/≥50) 2/11 
HBeAg seropositivity (positive/negative)  7/8
Hepatitis of all causes, n (%)   5 (10.2%)   16 (34.8%)  0.004 
Enhanced replication  4 (8.2%)  11 (23.9%)  0.036 
Other causes
† 1 5 
Hepatic decompensation of all causes, n (%)  0 (0%)   5 (10.9%)  0.018 
Enhanced replication  0  3 
Other causes  0  2 
*P-value by Mann-Whitney U-test, 
†Drug-related hepatitis and treatment-related liver toxicity during TACL.
HCV, hepatitis C virus; HBV, hepatitis B virus.
Table 3. Characteristics of the four patients with hepatitis attributed to enhanced replication of HCV
Patient 
1 2 3 4 
Baseline Sex/age
HCV genotype
ALT/TB
HCV RNA
M/51 
 2 
30/0.1 
<50
M/74 
Ib 
33/0.8 
<50 
F/70 
NT 
45/0.8 
2,500
M/73 
 2 
42/0.5 
9,560
TACL Agents
No. of cycles to enhanced replication
Doxo 
 2 
Epi/Cis 
 2 
Doxo 
 1 
Epi/Cis
 3 
At the time of
reactivation
Onset of enhanced replication 
after the last TACL (days)
ALT/TB (peak level)
HCV RNA 
Development of decompensation
30
115/0.4
31,400 
No
29 
925/1.87
21,200 
No
35 
143/1.1
31,100 
No
22
142/0.5
96,100 
No
Follow-up  Days after onset of enhanced replication
HCV RNA
ALT/TB
   30
7,130
93/0.9
 54 
<50
24/1.21
   50
1,840
42/1.0
- 
NT
- 
HCV, hepatitis C virus; Epi, epirubicin; Cis, cisplatin; Doxo, doxorubicin; TACL, transarterial chemo-lipiodolization; NT, not tested; 
ALT, alanine aminotransferase (<36 IU/L); TB, total bilirubin (<1.2 mg/dL); HCV RNA (<50 copies/mL).
replication, including three patients with hepatitis, got 
subsequent TACL, although the time interval between each 
subsequent TACL was longer than scheduled with three hepatitis 
patients. None of the patients with enhanced HCV replication 
during TACL underwent further antiviral treatment.
Comparison of the HCV seropositive group (n=49) with 
the HBV seropositive group (n=46) revealed no significant 
difference in the frequency of viral reactivation. However, 
statistically significant differences were observed in the 
frequency of hepatitis (P=0.036) due to viral reactivation 
and hepatic decompensation (P=0.018) between these two 
groups. The mean number of treatment cycles to enhanced 
viral replication was 2.3 for HCV seropositive group (n=13) 
and 1.9 for HBV seropositive group (n=15), but the difference 
was not statistically significant.
The clinical features of four patients with hepatitis 
attributed to enhanced HCV replication during TACL are 
shown in Table 3. The elevation of ALT was mild, except in 304  The Korean Journal of Hepatology Vol. 17. No. 4, December 2011
Table 4. Univariate analysis of factors related to enhanced replication of HCV during TACL
Patients with enhanced
replication (n=13)
Patients without enhanced
replication (n=36)
P-value 
Age (years)  65.8±7.0  66.3±10.6 0.793
*
Sex (M:F)  8:5  26:10  0.484
†
ALT (IU/L)  58.5±27.0  49.8±33.8  0.403
*
Total bilirubin (mg/dL)  0.84±0.57  1.07±0.64  0.422
*
Baseline HCV RNA (copies/mL)  338172 (<50-2,510,000)  5457500 (<50-52,700,000)  0.092
*
AFP (ng/mL)  132.3 (5.0-1061.0)  439.8 (3.0-4232.0)  0.288
*
HCV genotype  0.979
†
Ib 5/11 13/22
Other types  6/11 9/22
Type of chemotherapy  0.315
†
Epi/Doxo+Cis 10 22 
Epi/Doxo or Cis alone   3 14 
Total number of cycles  3.6±0.9  3.8±2.3  0.804
*
Child-Pugh classification  0.734
†
A1 2 3 2
B or C  1  4
Values are expressed as mean±SD for continuous variables except AFP [median (range)].
*P-value by Mann-Whitney U-test, 
†P-value by Fisher’s exact test.
HCV, hepatitis C virus; ALT, alanine aminotransferase; AFP, α-fetoprotein; Epi, epirubicin; Cis, cisplatin; Doxo, doxorubicin; TACL, 
transarterial chemo-lipiodolization.
one person (patient 2), who had a past history of excessive 
alcohol use. Hepatitis due to enhanced HCV replication was 
usually milder than in cases with HBV reactivation, with a 
median ALT level of 142.5 IU/L versus 303.5 IU/L, respectively. 
None of the four patients with hepatitis evidenced hepatic 
decompensation due to enhanced HCV replication during 
TACL. Follow-up HCV RNA was checked in three of four 
patients with variable time intervals, and HCV RNA 
titer and ALT level decreased without antiviral treatment 
(Table 3).
Factors associated with enhanced HCV replication
To evaluate the clinical factors related to the enhancement 
of HCV replication during TACL, 10 variables were compared 
in patients with and without enhanced HCV replication 
during TACL (Table 4). No statistically significant factors 
were found, including baseline HCV RNA copies or HCV 
genotypes.
DISCUSSION
The reactivation of hepatitis virus during systemic 
chemotherapy for malignancies is a significant problem 
that can lead to hepatic failure.
15 The mechanism of viral 
reactivation is unclear but may involve a two-stage process, 
as described by Xunrong et al.
16 The first or initial stage is 
characterized by a dramatic increase in viral replication and 
active infection of hepatocytes while the patient is being 
treated with cytotoxic agents. After withdrawal of the 
cytotoxic agents, a second stage with restoration of the 
immune function mediated by T-cells and destruction of 
infected hepatocytes occurs.
17 This immune reconstitution 
phase can lead to biochemical and clinical hepatitis, with 
transient elevation of ALT, possible jaundice, development 
of constitutional symptoms, and even hepatic decompensation. 
This process has been emphasized more frequently in HBV 
infection than in HCV, and preemptive antiviral therapy 
against HBV has been proven to be efficacious to prevent 
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chemotherapy and TACE.
17-22
TACL has been shown to reactivate HBV infection in 
previous reports,
  and its immunosuppressive effect on 
chemotherapeutic agents infused during TACL was the 
suggested mechanism.
10,19 HCV replication was also enhanced 
during TACL, and no statistically significant difference in 
the frequency of viral reactivation between HBV and HCV 
was observed in this study. However, no relevant clinical 
factors that contributed to HCV reactivation during TACL 
were identified. Previous studies reported that genotype 2c 
carriers are at high risk of hepatitis reactivation in an 
untreated cohort of patients with chronic HCV infection.
23 
There was also a case series suggesting that HCV genotype 2 
might be a risk factor for reactivation in patients with B-cell 
lymphoma undergoing rituximab combination chemotherapy.
24 
But we were unable to identify an association between 
enhanced replication of HCV and viral genotype.
Interestingly, two patients with initially undetectable 
HCV RNA titers later developed enhanced viral replication. 
Anti-HCV positive patients without HCV RNA for more 
than 6 months are considered to be cured of hepatitis C. 
These patients have cleared the virus either spontaneously or 
due to treatment. Of our two patients, one had no history of 
treatment, and the other had undergone interferon therapy. It 
is generally believed that hepatitis C virus is not completely 
eliminated from the body but is under control of the immune 
system. HCV RNA has been reported to be present in the 
liver and peripheral blood mononuclear cells of patients 
with no detectable serum HCV RNA.
25,26
The possible cause for enhanced replication of HCV 
during TACL can be suggested, considering the attenuated 
activity of cellular immune response in liver by TACL. 
Previous studies showed that HCV viremia recurred in a 
patient and in a chimpanzee after serum samples consistently 
tested negative for HCV RNA using a nested reverse- 
transcription PCR method for 4 months after normalization 
of ALT levels.
27,28 In both cases, loss of HCV specific CD4+ 
T-cell responses preceded HCV recurrence. Additionally, in 
vivo  depletion of CD8+ T cells resulted in prolonged 
viremia, which was controlled only when HCV-specific 
CD8+ T cells reappeared in the liver.
29 Taken together, these 
studies indicate that the adaptive cellular immune system, 
whose important components are CD4+ and CD8+ T cells, is 
crucial in controlling HCV replication, and attenuated 
activity of the cellular immune response can result in 
enhanced HCV replication in the liver.
Our study showed that the hepatitis and/or hepatic decom-
pensation attributed to enhanced replication of HCV during 
TACL was significantly less frequent than that of HBV. This 
phenomenon may be the result of different immunogenic 
characteristics between these two viruses. A recent study 
described that human HCV-specific T cells differ in their 
effector functions from human HBV-specific T cells. Whereas 
HBV-specific CD8+ T cells express high levels of perforin 
and show vigorous proliferation, IFN-γ production, and 
cytotoxic activity on in vitro stimulation,
30 these effector 
functions are reduced in HCV-specific T cells.
30-32 The 
different degree of cytotoxicity between HBV-specific and 
HCV-specific CD8+ cells may contribute to a different pattern 
of viral reactivation and of hepatitis due to reactivation.
Additionally, HCV has escape mechanisms that contribute 
to the high chronicity rate of the viral infection and the 
attenuated course of new infections. These escape mechanisms 
might also prevent serious immune-mediated hepatic 
damage after enhanced viral replication during TACL. One 
important escape mechanism is viral-sequence mutations,
33 
and several other mechanisms might also contribute to the 
observed impairment of HCV-specific immune responses.
In conclusion, TACL can enhance replication of HCV, but 
the possibility of hepatitis and hepatic decompensation 
attributed to enhanced HCV replication would be lower than 
that of HBV reactivation in patients undergoing TACL. This 
discrepancy may result from differences in immunogenicity 
between HBV and HCV. Further prospective studies with 
large numbers of patients are required to confirm this suggestion. 
Concomitantly, the necessity of preemptive and/or targeted 
antiviral therapy for enhanced HCV replication during 
TACL should be evaluated.
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